HeimAAVXF • OTCMKTS
add
Abivax SA
Við síðustu lokun
11,05 $
Árabil
10,19 $ - 15,15 $
Markaðsvirði
603,83 m. EUR
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
EPA
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 3,39 m. | 201,87% |
Rekstrarkostnaður | 43,39 m. | 119,55% |
Nettótekjur | -40,82 m. | -57,14% |
Hagnaðarhlutfall | -1,20 þ. | 47,94% |
Hagnaður á hvern hlut | — | — |
EBITDA | -39,91 m. | -114,56% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 222,32 m. | 94,37% |
Heildareignir | 284,49 m. | 66,29% |
Heildarskuldir | 158,02 m. | 74,43% |
Eigið fé alls | 126,47 m. | — |
Útistandandi hlutabréf | 62,92 m. | — |
Eiginfjárgengi | 5,50 | — |
Arðsemi eigna | -35,15% | — |
Ávöxtun eigin fjár | -41,69% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -40,82 m. | -57,14% |
Handbært fé frá rekstri | -42,59 m. | -208,62% |
Reiðufé frá fjárfestingum | 6,73 m. | 886,10% |
Reiðufé frá fjármögnun | 20,16 m. | -65,46% |
Breyting á handbæru fé | -14,81 m. | -133,88% |
Frjálst peningaflæði | -21,07 m. | -45,88% |
Um
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Framkvæmdastjóri
Stofnsett
4. des. 2013
Vefsvæði
Starfsfólk
62
